Staar Surgical Company (STAA)
Summary
STAAR Surgical Company (STAA) Discusses Differentiation of EVO ICL Technology and Market Trends in Refractive Surgery Transcript
STAAR Surgical Company (STAA) Discusses Differentiation of EVO ICL Technology and Market Trends in Refractive Surgery Transcript
STAAR Surgical Q1 2026: Early Signs Of A Durable Turnaround
STAAR Surgical Company delivered a robust 1Q26 beat, with revenue up 119% YoY to $93.5M and a swing to $5.2M net income. China's market rebound, normalized inventory, and rapid EVO+ ICL adoption drove topline strength, while disciplined OpEx and manufacturing efficiency boosted margins to 73.6%. STAA is benefiting from a structural shift toward lens-based refractive surgery, gaining U.S. share despite a shrinking laser market and expanding its addressable market via FDA approval.
STAAR Surgical Company (STAA) Q1 2026 Earnings Call Transcript
STAAR Surgical Company (STAA) Q1 2026 Earnings Call Transcript
Staar Surgical Company Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 120 | $3,482.6 | $3,355.8 | -$126.8 | -3.64% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 35 | $617.05 | $978.76 | $361.71 | 58.62% |
 Point72 Asset Management LP Point72 Asset Management LP | 823,152 | $15.39M | $23.01M | $7.61M | 49.47% |
 Defender Capital Defender Capital LLC | 431,187 | $16.87M | $12.05M | -$4.82M | -28.58% |
 Madison Avenue Partners LP Madison Avenue Partners LP | 2.44M | $45.66M | $68.23M | $22.57M | 49.44% |
Staar Surgical Company (STAA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Staar Surgical Company ever had a stock split?
Staar Surgical Company Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Warren Foust CEO | NASDAQ (NMS) Exchange | 852312305 CUSIP |
| US Country | 1,157 Employees | - Last Dividend | 18 May 1992 Last Split | 15 Jul 1983 IPO Date |
Overview
STAAR Surgical Company stands at the forefront of ophthalmic innovation, specialized in designing, developing, manufacturing, marketing, and selling implantable lenses for the eye, alongside companion delivery systems. Since its incorporation in 1982, STAAR Surgical has established itself as a pioneer in providing advanced solutions for visual disorders. Headquartered in Lake Forest, California, the company embarks on its mission to improve vision and enhance the quality of life for patients globally. By catering to health care providers such as ophthalmic surgeons, vision and surgical centers, hospitals, and government facilities, STAAR Surgical's reach extends widely across the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. Moreover, the company's global footprint expands through a network of representatives and independent distributors in regions such as China, Korea, India, France, Benelux, and Italy.
Products and Services
- Implantable Collamer Lens (ICL) Product Family: STAAR Surgical's flagship offering includes a variety of ICLs designed to correct visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia. The innovative lenses are implanted into the eye to provide a long-term solution that can eliminate or reduce the need for glasses or contact lenses. These lenses are favored for their biocompatibility, thanks to the unique Collamer material, and their ability to provide high-quality vision correction with minimal maintenance.
- Companion Delivery Systems: To enhance the effectiveness and safety of lens implantation, STAAR Surgical also provides specially designed delivery systems. These systems facilitate the precise and controlled delivery of the implantable lenses into the eye, ensuring a smooth surgical experience for both healthcare professionals and patients. The delivery systems are an integral part of the company’s portfolio, supporting the deployment of ICLs and contributing to their high success rate in vision correction.
